Colic Clinical Trial
Official title:
Evaluation of the Effectiveness of Probiotic Strains (L. Reuteri CCT 7862) and (B. Lactis CCT 7858 + L. Rhamnosus - CCT 7863) in Reducing Colic and Improving Gastrointestinal Health in Newborn
Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Therefore, based on data in the literature, it is understood that there is evidence of the effectiveness of using probiotics, either alone or in the form of a blend, to alleviate the symptoms of infantile colic.
Infantile colic represents a self-limiting temporary condition, which occurs in about one in five babies in the first few months of life, and is characterized by inconsolable crying and fussiness of unknown cause. Despite its benign nature, infantile colic serves as a significant source of maternal anxiety and depression, impaired family functioning, and the most common reason for seeking medical advice in this age group. Infant colic is also associated with sleep problems in babies. Parents and caregivers often seek medical attention for colic, including the use of medication, plant fiber, lactase, sucrose solution, hypoallergenic diet, and herbal tea. However, there is no single effective and safe intervention for infantile colic. Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Thus, several researchers have suggested that probiotics may be useful in treating breastfed babies with colic and reducing crying time. One study showed that administration of Lactobacillus reuteri DSM 17938 improved colic symptoms, although the effectiveness was only seen in breastfed and not formula fed infants. Another study showed that treatment with a combination of L. casei, L. rhamnosus, Streptococcus thermophilus, B. breve, L. acidophilus, B. infantiles, L. bulgaricus and fructooligosaccharides (FOS) reduced the duration of crying by almost 35 min compared to placebo. Furthermore, other authors has reported a reduced incidence of caregiver-reported colic when infants were supplemented with a combination of B. animalis subsp. lactis BB-12 and an unidentified strain of S. thermophilus, although colic was not formally diagnosed by a physician, which reduced the strength of the studies. A recent study on the same BB-12 strain overcame this deficiency by formally diagnosing colic using Rome-III criteria. However, this study showed that the response rate did not significantly improve over placebo until day 21. On the other hand, one study reported that the use of L. rhamnosus GG (ATCC53103) had no significant effect on crying in babies with colic. In another study, no significant differences were found in crying and irritability between the probiotic and placebo groups when supplemented with L. reuteri ATCC55730 or B. lactis BB-12. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01849991 -
Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic
|
Phase 1 | |
Completed |
NCT01279265 -
Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic
|
N/A | |
Completed |
NCT00177086 -
Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi
|
Phase 3 | |
Not yet recruiting |
NCT02577133 -
Prevention of Colic With the Probiotic Lactobacillus Reuteri
|
Phase 2/Phase 3 | |
Recruiting |
NCT01715220 -
Treatment of Suspected Cholelithiasis With Nitroglycerin
|
Phase 2 | |
Completed |
NCT00922727 -
Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults
|
Phase 1 | |
Completed |
NCT02865564 -
Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics
|
N/A | |
Completed |
NCT01997593 -
Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected
|
Phase 2 | |
Completed |
NCT01541046 -
Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic
|
Phase 2 | |
Completed |
NCT00929292 -
Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic
|
Phase 3 | |
Terminated |
NCT05554991 -
Human Milk Oligosaccharide (HMO) Supplementation in Colic Management
|
N/A | |
Recruiting |
NCT01067027 -
Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri
|
Phase 4 | |
Recruiting |
NCT04983069 -
Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
|
||
Withdrawn |
NCT05198700 -
The Effect of Probiotics on Symptoms of Infantile Colic
|
Phase 2 | |
Terminated |
NCT02586558 -
Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants
|
N/A | |
Completed |
NCT01532518 -
Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
|
Phase 2 | |
Completed |
NCT00796523 -
An Intervention to Decrease Infant Crying
|
N/A | |
Completed |
NCT05052476 -
First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic
|
N/A | |
Completed |
NCT02242292 -
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
|
Phase 2 | |
Terminated |
NCT00139646 -
Parecoxib in Renal Colic
|
Phase 3 |